Table 3.
Positive anti-IFX antibodies | Negative anti-IFX antibodies | P value | |
---|---|---|---|
Disease duration, mean, and months | 90.77 ± 49.56 | 128 ± 97.48 | 0.306 |
IFX treatment duration, mean, and months | 29.77 ± 17.01 | 38.77 ± 34.60 | 0.511 |
DAS28 at flare and mean | 5.09 ± 1.19 | 4.18 ± 1.67 | 0.189 |
DAS28 after 2 months and mean | 5.68 ± 0.8 | 3.95 ± 1.49 | 0.006 |
csDMARD association and nr (%) | 3 | 9 | 0.028 |
Differences between patient's characteristics were tested by Student's t-test or chi-square test.
IFX: infliximab; csDMARD: conventional synthetic disease modifying antirheumatic drug.